Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.

Valerie GlutschHermann KneitzAnja GesierichMatthias GoebelerSebastian HaferkampJürgen C BeckerSelma UgurelBastian Schilling

Published in: Cancer immunology, immunotherapy : CII (2021)

In this small retrospective study, we observed a high response rate and durable responses to subsequent combined immunotherapy with IPI/NIVO in avelumab-refractory metastatic MCC patients. In conclusion, our data suggest a promising activity of second- or third-line PD-1- plus CTLA-4-blockade in patients with anti-PD-L1-refractory MCC.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
small cell lung cancer
prognostic factors
machine learning
patient reported
artificial intelligence